@xconomy.com 1 year ago
Acelity Sells to 3M in Deal Valued at $6.7 Billion, Ending IPO Plan
@xconomy.com 1 year ago
San Antonio Wound-Care Company Eyes (Another) Initial Public Offering
@xconomy.com 1 year ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com 1 year ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com 1 year ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com 1 year ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com 1 year ago
San Antonio Life Science Business Acelity Cuts 260 Jobs in Texas, NC
@xconomy.com 1 year ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More